IRIS
MUSTO, Pellegrino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.949
AS - Asia 7.569
EU - Europa 6.374
SA - Sud America 3.333
Continente sconosciuto - Info sul continente non disponibili 1.062
AF - Africa 452
OC - Oceania 9
Totale 33.748
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.244
IT - Italia 3.028
SG - Singapore 2.707
BR - Brasile 2.636
HK - Hong Kong 1.311
CN - Cina 1.247
VN - Vietnam 842
RU - Federazione Russa 739
FR - Francia 572
SE - Svezia 556
DE - Germania 472
GB - Regno Unito 366
BD - Bangladesh 319
CA - Canada 282
AR - Argentina 255
IN - India 238
FI - Finlandia 188
MX - Messico 117
ID - Indonesia 114
IQ - Iraq 109
EC - Ecuador 102
CO - Colombia 98
ZA - Sudafrica 98
TR - Turchia 96
PK - Pakistan 85
CI - Costa d'Avorio 78
VE - Venezuela 73
SA - Arabia Saudita 61
PL - Polonia 60
MA - Marocco 58
UZ - Uzbekistan 58
PY - Paraguay 53
JP - Giappone 51
PH - Filippine 51
UA - Ucraina 51
CR - Costa Rica 50
NL - Olanda 50
AT - Austria 49
CL - Cile 47
TN - Tunisia 46
ES - Italia 41
SV - El Salvador 39
EG - Egitto 37
JM - Giamaica 37
IE - Irlanda 36
PE - Perù 36
MY - Malesia 34
HN - Honduras 32
KE - Kenya 29
IL - Israele 28
JO - Giordania 27
TT - Trinidad e Tobago 27
AZ - Azerbaigian 25
GT - Guatemala 25
NI - Nicaragua 25
LT - Lituania 24
PR - Porto Rico 24
CZ - Repubblica Ceca 22
DZ - Algeria 21
NP - Nepal 20
KZ - Kazakistan 19
CW - ???statistics.table.value.countryCode.CW??? 18
ET - Etiopia 18
BE - Belgio 15
BO - Bolivia 15
OM - Oman 14
AE - Emirati Arabi Uniti 13
CH - Svizzera 13
SN - Senegal 13
TH - Thailandia 13
UY - Uruguay 12
DO - Repubblica Dominicana 11
EE - Estonia 11
KR - Corea 10
LB - Libano 10
SC - Seychelles 10
AL - Albania 9
PA - Panama 9
RS - Serbia 9
BB - Barbados 8
BH - Bahrain 8
GP - Guadalupe 8
GR - Grecia 8
PS - Palestinian Territory 8
SY - Repubblica araba siriana 8
AU - Australia 7
BG - Bulgaria 7
DK - Danimarca 7
KG - Kirghizistan 7
XK - ???statistics.table.value.countryCode.XK??? 7
AO - Angola 6
BY - Bielorussia 6
GE - Georgia 6
TW - Taiwan 6
HR - Croazia 5
HU - Ungheria 5
LV - Lettonia 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
GY - Guiana 4
Totale 32.622
Salva come PNG Salva come JPEG
Città #
Ashburn 1.869
San Jose 1.567
Singapore 1.519
Hong Kong 1.278
Milan 1.142
Fairfield 1.073
New York 592
Council Bluffs 520
Nyköping 453
Chandler 395
Woodbridge 395
Houston 377
Rome 369
Lawrence 346
Seattle 343
Lauterbourg 340
Cambridge 338
Beijing 327
Ho Chi Minh City 308
Wilmington 299
Roxbury 284
Des Moines 241
Santa Clara 220
Ann Arbor 218
São Paulo 217
Los Angeles 214
Dallas 186
Hanoi 167
Helsinki 145
San Diego 131
Falkenstein 116
Paris 114
Bari 113
Boardman 100
Columbus 100
London 96
Chicago 89
Munich 87
Figino 83
Abidjan 78
Princeton 78
Buffalo 74
Phoenix 74
Turin 74
The Dalles 70
Atlanta 68
Brooklyn 64
Rio de Janeiro 64
Frankfurt am Main 63
Nuremberg 59
Naples 55
Jakarta 54
Tashkent 54
Jacksonville 52
Toronto 52
Brasília 51
North Bergen 50
Belo Horizonte 48
Matera 48
Johannesburg 47
Montreal 47
Moscow 47
Porto Alegre 47
Potenza 47
Warsaw 47
Inglewood 43
Tokyo 42
Campinas 41
Curitiba 41
Guayaquil 40
Mexico City 40
Baghdad 39
Da Nang 39
San Francisco 39
Orem 38
San José 38
Denver 37
Dhaka 36
Chennai 35
Dublin 34
Haiphong 34
Shanghai 34
San Salvador 33
Guangzhou 29
Medellín 29
Quito 29
Salvador 29
Nanjing 28
Florence 27
Jeddah 27
Ribeirão Preto 27
Amman 26
Buenos Aires 26
Salt Lake City 25
Managua 24
Nairobi 24
Karachi 23
Guarulhos 22
Lahore 22
Lima 22
Totale 19.405
Salva come PNG Salva come JPEG
Nome #
Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA 221
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 220
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets 204
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 204
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 197
Cardiovascular events and intensity of treatment in polycythemia vera. 194
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 188
Overall and complication‐free survival in a large cohort of patients with β‐thalassemia major followed over 50 years 182
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 180
Amyloid in bone marrow smears of patients affected by multiple myeloma 173
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response 172
90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma 165
Differences among young adults, adults, and elderly chronic myeloid leukemia patients. 160
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 154
After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia 153
Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link? 149
Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick 146
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 145
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 145
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 143
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 143
Global methylation patterns in primary plasma cell leukemia 141
Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs 140
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 139
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 138
RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia 138
Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells 137
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 134
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 133
Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma 133
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 131
FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. 131
Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia 130
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 126
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma 126
Epitranscriptomics in normal and malignant hematopoiesis 124
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project 124
The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells 124
Case report: biallelic DNMT3A mutations in acute myeloid leukemia 122
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 120
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study 119
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity 119
What Is New in the Treatment of Smoldering Multiple Myeloma? 118
Can the new and old drugs exert an immunomodulatory effect in acute myeloid leukemia? 117
Exploring the Potential of Eltrombopag: Room for More? 116
Analysis of amount, size, protein phenotype and molecular content of circulating extracellular vesicles identifies new biomarkers in multiple myeloma 116
Single-Cell Sequencing: Ariadne's Thread in the Maze of Acute Myeloid Leukemia 114
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 114
Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia 113
Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study 113
90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma 111
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 111
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study) 110
IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis 109
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 108
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 107
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients 107
IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater? 106
Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma 106
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 106
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival 105
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: A pooled analysis of two studies 105
Optical Genome Mapping as a Tool to Unveil New Molecular Findings in Hematological Patients with Complex Chromosomal Rearrangements 104
JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander? 104
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial 104
Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia 103
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 103
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial 103
TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition? 102
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 101
Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why? 101
null 101
Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients 101
Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients 101
Hypereosinophilia with a pinch of salt and pepper 101
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 100
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 99
Immunomodulatory drugs in acute myeloid leukemia treatment 99
The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy 98
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event 98
Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia 97
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 97
Clonal hematopoiesis in clinical practice: walking a tightrope 96
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 96
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 96
Gastric normal adjacent mucosa versus healthy and cancer tissues: Distinctive transcriptomic profiles and biological features 96
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice 96
The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms 95
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma 95
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach. 95
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. 95
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients 94
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma 94
The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation 94
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 93
Advanced mast cell disease: an Italian Hematological Multicenter experience 93
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia 92
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 92
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches 92
Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network 91
Totale 12.291
Salva come PNG Salva come JPEG
Categoria #
all - tutte 195.761
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 195.761
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.627 0 0 0 0 20 291 110 85 244 196 287 394
2022/20231.717 404 234 142 66 102 192 111 142 232 18 46 28
2023/20241.196 97 139 78 56 102 460 57 28 2 14 22 141
2024/20255.918 158 25 399 102 152 616 543 425 340 384 882 1.892
2025/202614.665 1.795 632 1.064 1.862 1.274 615 1.175 534 1.560 1.587 512 2.055
2026/20275.083 650 844 1.156 2.394 39 0 0 0 0 0 0 0
Totale 33.748